DGX

DGX

USD

Quest Diagnostics Incorporated Common Stock

$178.030-1.320 (-0.736%)

Preço em tempo real

Healthcare
Diagnostics & Research
Estados Unidos

Gráfico de preços

Loading Chart...

Métricas-chave

Métricas de mercado
Fundamentos da empresa
Estatísticas de negociação

Métricas de mercado

Abertura

$179.350

Máximo

$180.040

Mínimo

$176.310

Volume

0.20M

Fundamentos da empresa

Capitalização de mercado

19.8B

Setor

Diagnostics & Research

País

United States

Estatísticas de negociação

Volume médio

0.90M

Bolsa de valores

NYQ

Moeda

USD

Faixa de 52 semanas

Mínimo $148.7Atual $178.030Máximo $197.55

Notícias relacionadas

PR Newswire

New Study Demonstrates Accuracy of Two Quest AD-Detect® Tests for Alzheimer's Disease Diagnosis

Two blood tests, each involving multiple biomarkers, are highly accurate at identifying Alzheimer's disease pathology in symptomatic patients,...

Ver mais
New Study Demonstrates Accuracy of Two Quest AD-Detect® Tests for Alzheimer's Disease Diagnosis
Analyst Upgrades

Barclays Maintains Equal-Weight on Quest Diagnostics, Raises Price Target to $195

Barclays analyst Stephanie Davis maintains Quest Diagnostics with a Equal-Weight and raises the price target from $190 to $195.

Ver mais
Barclays Maintains Equal-Weight on Quest Diagnostics, Raises Price Target to $195
Analyst Upgrades

Truist Securities Maintains Hold on Quest Diagnostics, Raises Price Target to $205

Truist Securities analyst David Macdonald maintains Quest Diagnostics with a Hold and raises the price target from $195 to $205.

Ver mais
Truist Securities Maintains Hold on Quest Diagnostics, Raises Price Target to $205
Analyst Upgrades

Leerink Partners Maintains Outperform on Quest Diagnostics, Raises Price Target to $210

Leerink Partners analyst Michael Cherny maintains Quest Diagnostics with a Outperform and raises the price target from $203 to $210.

Ver mais
Leerink Partners Maintains Outperform on Quest Diagnostics, Raises Price Target to $210
PR Newswire

Quest Diagnostics Reports Third Quarter 2025 Financial Results; Raises Guidance for Full Year 2025

Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the third...

Ver mais
Quest Diagnostics Reports Third Quarter 2025 Financial Results; Raises Guidance for Full Year 2025
Analyst Upgrades

Evercore ISI Group Maintains In-Line on Quest Diagnostics, Raises Price Target to $190

Evercore ISI Group analyst Elizabeth Anderson maintains Quest Diagnostics with a In-Line and raises the price target from $185 to $190.

Mantenha-se atualizado

Defina um alerta de preço, obtenha atualizações de análise de IA e notícias de mercado em tempo real.